+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Minimal Residual Disease Testing Market by Test Type (Cytogenetics, Flow Cytometry, Next-Generation Sequencing (NGS)), Application Areas (Leukemia, Lymphoma, Multiple Myeloma), End-User Vertical - Global Forecast 2025-2030- Product Image
Minimal Residual Disease Testing Market by Test Type (Cytogenetics, Flow Cytometry, Next-Generation Sequencing (NGS)), Application Areas (Leukemia, Lymphoma, Multiple Myeloma), End-User Vertical - Global Forecast 2025-2030- Product Image
Sale

Minimal Residual Disease Testing Market by Test Type (Cytogenetics, Flow Cytometry, Next-Generation Sequencing (NGS)), Application Areas (Leukemia, Lymphoma, Multiple Myeloma), End-User Vertical - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5847005
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The minimal residual disease (MRD) testing market is rapidly redefining how precision oncology is delivered, empowering providers with actionable tools to improve clinical outcomes and operational efficiency. This report offers a comprehensive review of the market’s transformative shifts, equipping senior decision-makers with the insight needed for optimal strategy in a complex, evolving landscape.

Market Snapshot: Minimal Residual Disease Testing Market Performance and Growth

The minimal residual disease testing market grew from USD 1.87 billion in 2024 to USD 2.08 billion in 2025. It is expected to continue growing at a CAGR of 11.18%, reaching USD 3.54 billion by 2030. Market expansion is propelled by advancements in molecular and cellular assay technologies, expanded regulatory guidance, and increasing adoption across clinical settings. Pioneering applications in oncology, coupled with greater investment in personalized care pathways, are accelerating the integration of MRD testing into routine diagnostics.

Scope & Segmentation of the Minimal Residual Disease Testing Market

  • Test Types: Cytogenetics (chromosomal microarray, fluorescence in situ hybridization), flow cytometry (multi-parameter, single-parameter formats), next-generation sequencing (targeted and whole genome sequencing), polymerase chain reaction (digital and quantitative PCR).
  • Application Areas: MRD testing protocols are widely used in leukemia subtypes (acute lymphoblastic, acute myeloid, chronic lymphocytic), lymphoma (Hodgkin’s and non-Hodgkin’s), multiple myeloma, and increasingly across solid tumors such as breast and colorectal cancers.
  • End-User Verticals: Academic and research institutes lead method validation, biopharmaceutical companies incorporate MRD markers in clinical trials, diagnostic laboratories deliver high-throughput services, and hospitals integrate assay results in clinical workflows.
  • Regional Scope: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with major healthcare markets such as the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, among others), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: The market features established and emerging players such as Agilus Diagnostics, Amgen, Adaptive Biotechnologies, ARUP Laboratories, AstraZeneca, Asuragen (Bio-Techne), Bio-Rad Laboratories, Bristol-Myers Squibb, C2I Genomics, Cergentis, Exact Sciences, Roche, Genetron Holdings, GRAIL, Guardant Health, Integrated DNA Technologies, Invivoscribe, Kite Pharma (Gilead Sciences), Laboratory Corporation of America, Mdxhealth, MedGenome, Mission Bio, Myriad Genetics, Natera, NeoGenomics, OPKO Health, Quest Diagnostics, Sysmex, and Veracyte.

Key Takeaways for Senior Decision-Makers

  • Market growth is strongly influenced by the transition of MRD assays from research laboratories to routine clinical use, enabled by technology convergence and improved clinical workflows.
  • Leading institutions are actively validating MRD tests and developing new algorithms for therapy management and early relapse intervention, setting new standards in data-driven clinical care.
  • Ultra-sensitive sequencing and digital quantification methods are driving detection limits lower, facilitating earlier interventions for hematologic and select solid tumor indications.
  • Regulatory agencies are increasingly shaping the market by clarifying compliance expectations, while evolving reimbursement models encourage broader access to advanced MRD diagnostics.
  • Strategic partnerships across diagnostics, pharma, and technology providers are facilitating rapid clinical translation and driving workflow innovation.
  • Regional variation in adoption reflects differences in healthcare infrastructure, policy, and public-private investment in precision medicine solutions.

Tariff Impact: Implications of 2025 U.S. Tariffs on the MRD Testing Value Chain

The imposition of new tariffs in the United States in 2025 has created cost pressures for laboratories reliant on imported instruments, reagents, and consumables. This has prompted some providers to reconsider supply contracts and diversify sourcing strategies. Manufacturers now face increased regulatory complexity, balancing U.S. trade policy with international quality obligations. While some regional distributors and partnerships are stabilizing supply continuity, laboratories are adapting inventory management to mitigate lead time extensions and fluctuating costs.

Methodology & Data Sources

This research integrates comprehensive desk reviews of scientific literature, regulatory filings, and proprietary databases, with insights from interviews with laboratory directors, oncologists, and executives in R&D. Quantitative data triangulation and validation workshops ensure accurate, globally representative findings.

Why This Report Matters

  • Provides a data-grounded analysis for prioritizing strategic investments in MRD assay technologies and supporting infrastructure.
  • Enables stakeholder alignment on regulatory compliance, operational efficiency, and reimbursement readiness for precision oncology solutions.
  • Supports informed decision-making by contextualizing emerging trends, partnership dynamics, and regional adoption patterns in minimal residual disease testing.

Conclusion

With strong momentum in technology, regulatory guidance, and clinical adoption, the minimal residual disease testing market is positioned at the frontier of precision oncology. Stakeholders leveraging these insights can drive meaningful improvements in patient care and operational outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of liquid biopsy techniques for non-invasive residual disease monitoring
5.2. Advancements in digital PCR technology enhancing sensitivity of disease detection
5.3. Rising investment in research focusing on minimal residual disease to support early treatment intervention strategies
5.4. Development of standardized protocols for minimal residual disease assessment across laboratories
5.5. Integration of artificial intelligence tools to improve accuracy and interpretation of minimal residual disease data
5.6. Increasing use of MRD status as a prognostic biomarker in hematologic malignancies
5.7. Rapid growth in the adoption of liquid biopsy techniques for non-invasive monitoring of minimal residual disease
5.8. Focus on cost-effectiveness and accessibility to broaden the reach of minimal residual disease testing in healthcare systems
5.9. Collaborations between diagnostic firms and biopharma to develop companion MRD tests
5.10. Expanding applications of minimal residual disease testing in personalized cancer therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Minimal Residual Disease Testing Market, by Test Type
8.1. Introduction
8.2. Cytogenetics
8.2.1. Chromosomal microarray
8.2.2. Fluorescence in situ hybridization (FISH)
8.3. Flow Cytometry
8.3.1. Multi-parameter flow cytometry
8.3.2. Single-parameter flow cytometry
8.4. Next-Generation Sequencing (NGS)
8.4.1. Targeted sequencing
8.4.2. Whole genome sequencing
8.5. Polymerase Chain Reaction (PCR)
8.5.1. Digital PCR
8.5.2. Quantitative PCR
9. Minimal Residual Disease Testing Market, by Application Areas
9.1. Introduction
9.2. Leukemia
9.2.1. Acute Lymphoblastic Leukemia (ALL)
9.2.2. Acute Myeloid Leukemia (AML)
9.2.3. Chronic Lymphocytic Leukemia (CLL)
9.3. Lymphoma
9.3.1. Hodgkin’s lymphoma
9.3.2. Non-Hodgkin’s lymphoma
9.4. Multiple Myeloma
9.5. Solid Tumors
9.5.1. Breast cancer
9.5.2. Colorectal cancer
10. Minimal Residual Disease Testing Market, by End-User Vertical
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Biopharmaceutical Companies
10.4. Diagnostic Laboratories
10.5. Hospitals
11. Americas Minimal Residual Disease Testing Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Minimal Residual Disease Testing Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Minimal Residual Disease Testing Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Agilus Diagnostics Ltd.
14.3.2. Amgen Inc.
14.3.3. Adaptive Biotechnologies Corporation
14.3.4. ARUP Laboratories
14.3.5. AstraZeneca PLC
14.3.6. Asuragen Inc. by Bio-Techne Corporation
14.3.7. Bio-Rad Laboratories, Inc.
14.3.8. Bristol-Myers Squibb Company
14.3.9. C2I Genomics Inc.
14.3.10. Cergentis B.V.
14.3.11. Exact Sciences Corporation
14.3.12. F. Hoffmann-La Roche Ltd.
14.3.13. Genetron Holdings Limited
14.3.14. GRAIL, LLC by Illumina, Inc.
14.3.15. Guardant Health, Inc.
14.3.16. Integrated DNA Technologies, Inc.
14.3.17. Invivoscribe, Inc.
14.3.18. Kite Pharma, Inc. by Gilead Sciences, Inc.
14.3.19. Laboratory Corporation of America Holdings
14.3.20. Mdxhealth BV
14.3.21. MedGenome Inc
14.3.22. Mission Bio, Inc.
14.3.23. Myriad Genetics, Inc.
14.3.24. Natera Inc.
14.3.25. NeoGenomics Laboratories, Inc.
14.3.26. OPKO Health, Inc.
14.3.27. Quest Diagnostics incorporated
14.3.28. Sysmex Corporation
14.3.29. Veracyte, Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCHAI
FIGURE 22. MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCHSTATISTICS
FIGURE 23. MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCHCONTACTS
FIGURE 24. MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN’S LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN’S LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN’S LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN’S LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 90. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 91. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 92. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 93. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 129. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 130. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 131. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 132. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 133. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 134. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 135. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 136. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 137. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 138. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 139. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 140. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 141. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 142. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 143. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 144. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 145. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 146. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 147. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 154. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 155. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 156. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 157. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 158. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 160. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 161. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 162. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 163. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 166. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 174. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 175. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 176. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 177. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 249. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 250. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 251. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 252. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 253. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 254. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 255. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 256. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 257. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 258. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 259. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 260. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 261. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 262. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 263. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 264. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 265. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
TABLE 268. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2030 (USD MILLION)
TABLE 269. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 270. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 271. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
TABLE 272. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2030 (USD MILLION)
TABLE 273. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
TABLE 274. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2030 (USD MILLION)
TABLE 275. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
TABLE 276. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2030 (USD MILLION)
TABLE 277. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
TABLE 278. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2030 (USD MILLION)
TABLE 279. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
TABLE 280. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
TABLE 281. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 282. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 283. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 284. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 285. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 286. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
T

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Minimal Residual Disease Testing market report include:
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • Adaptive Biotechnologies Corporation
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • C2I Genomics Inc.
  • Cergentis B.V.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • Mdxhealth BV
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.54 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Minimal Residual Disease Testing Market 2025-2033 - Product Image

Minimal Residual Disease Testing Market 2025-2033

  • Report
  • 138 Pages
  • Global
From
Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031 - Product Image

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031

  • Report
  • 265 Pages
  • Global
From
Minimal Residual Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Minimal Residual Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), By Cancer Type (Hematological Malignancy, Solid Tumors), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), By Cancer Type (Hematological Malignancy, Solid Tumors), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 320 Pages
  • Global
From
Minimal Residual Disease Testing - Global Strategic Business Report - Product Image

Minimal Residual Disease Testing - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.